GERN News and Press, Geron Corporation From 02/24/26

2026-02-24 10:09:43 ET More on Geron Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade) Geron: From Launch Hype To Later-Line Gravity Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines Geron fo...

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following invest...

FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and bus...

2026-01-27 23:58:55 ET ... Read the full article on Seeking Alpha For further details see: Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade)

2026-01-12 08:46:48 ET More on Geron Geron: From Launch Hype To Later-Line Gravity Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help Geron st...

2026 RYTELO ® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology co...

2025-12-19 13:28:39 ET Introduction Geron’s stock ( GERN ) has underperformed the index ( SPY ) since my last look in May. Recall that Geron markets RYTELO in myelodysplastic syndrome, or MDS. While the drug is useful in certain patients, its actual TAM appears ni...

2025-12-16 17:49:59 ET More on Geron Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help Geron Corporation (GERN) Q3 2025 Earnings Call Transcript ...

2025-12-11 17:32:38 ET Investment Overview My last update on Geron ( GERN ) for Seeking Alpha was written in June, when shares in the commercial stage Pharma based in Foster City, California, traded at a value of $1.54, and its market cap was ~$1bn.... Read the full articl...

2025-12-11 09:14:20 ET More on Geron Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help Geron Corporation (GERN) Q3 2025 Earnings Call Transcript Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I Buy ...